Juno Therapeutics of Seattle said it is leasing a 68,000-square-foot building in Bothell for a biotech manufacturing facility to supply its clinical trials and potentially its first commercial products.

Share story

Juno Therapeutics of Seattle said it is leasing a 68,000-square-foot building in Bothell for a biotech manufacturing facility to supply its clinical trials and potentially its first commercial products.

The building is currently the headquarters of Oncogenex Pharmaceuticals, but spokesman Jim deNike says negotiations with landlord Biomed Realty may result in an agreement to relocate “at a considerable cost savings to the company.”

The plant, at 1522 217th Place in Bothell, will begin operations in early 2016, the company said in a press release. It included a statement from Gov. Jay Inslee, who said the plant “will increase Juno’s ability to provide their potentially lifesaving treatments to more patients across the country and will produce high wage jobs in the region.”

The company did not say how many people may be employed. Juno will pay $1.05 million the first year and $15.2 million over the full 10-year lease, according to a regulatory filing.

In a filing for its $264 million initial public offering in December, the company said it would use contract manufacturers for flexibility and to limit upfront costs, while also setting up its own manufacturing “to allow for better long-term margins and for the rapid implementation of innovations.”